There’s little doubt that COVID-19 has disrupted the clinical trials industry, with many pharmaceutical companies reconsidering the best ways to reach patients, and so it’s no surprise that one outcome of the pandemic is the drive towards direct to patient (DtP) trials where possible. Many sponsors recognise the benefits of increased patient diversity, improved patient recruitment and retention, and reduced site visits, particularly for vulnerable patients with compromised immune systems. Logistics companies are keen to benefit from the increased demand – writing a lot of online articles extolling the virtues of DtP trials! – but what does this potential shift mean for comparator sourcing companies? How can they prepare themselves for a possible change in the landscape of clinical trials?
Written by: Vanessa Dekou
Time taken to read: 10 minutes
Direct to patient trials have surged in popularity in the wake of the coronavirus pandemic, offering several benefits to patients and clinical trials sponsors. Vanessa Dekou, Managing Director at Clinical Services International, reflects on the opportunities and challenges this creates for comparator sourcing partners.
In most instances, clinical trials are conducted through test centres – often hospitals – in various countries around the world, with one or more centralised bases supplying the centres. In such a model, the logistics of comparator sourcing and delivery are orientated around these supply hubs. In contrast, DtP trials rely on timely supply to multiple depots where an authorised distributor takes over the supply chain. This multiplication of delivery sites introduces a significant degree of logistical complexity and introduces a further ‘node’ in the cold chain.
Simplicity does not precede complexity but follows it.
– Alan Perlis, computer scientist –
Hospital sites or test centres often have the storage facilities to handle all the necessary drugs for the duration of an entire clinical trial, so may only need to receive two to three deliveries, simplifying the comparator sourcing supply chain. In contrast, authorised distributors in DtP trials are unlikely to have the capacity to store clinical trial supplies on-site to then be distributed over an extended period. Instead, DtP trials rely on multiple ‘just-in-time’ deliveries to depots, for near immediate distribution to patients. A comparator sourcing solution needs to allow for an increase in the volume of deliveries with much tighter deadlines and less margin for error. At CSI, this is nothing new; we have a wealth of experience in running oncology trials that can include over 30 different medicines, all requiring just in time delivery. These are generally open-label trials, and patients often self-administer the drug, so the products are sourced locally. Although this adds considerable complexity, we have all the necessary tools to manage supplies with an excellent success rate.
This move towards patient administration and in-country sourcing has eliminated the need to relabel the medicine or comparator. Yet this potential advantage is not without its downsides. Locally sourcing comparators poses challenges, such as limited supply and a non-competitive market, making it harder to meet a sponsor’s competing desires for convenience and reduced cost. However, at CSI we put patient safety first and, to do that, we work either directly with manufacturers or authorised country distributors to ensure continuity of medication.
Cost, however you spin it, is still a primary concern for any clinical trial sponsor, and we understand that. Local sourcing and DtP distribution can carry significant cost implications, although these may be offset by certain advantages such as increased patient retention and compliance. Working with an experienced comparator sourcing partner with an extensive database and well-established relationships with manufacturers and suppliers will be even more crucial than ever in helping to develop the most effective and efficient comparator sourcing solution.
The nature of clinical trials may well be changing in the long term, but our commitment to excellent service and going above and beyond for our clients has stayed the same. Rather than tentatively edging towards the future, we’ve made bold steps to recruit new members to our team, expanding our reach and capabilities into Asia and the USA. If you have a comparator sourcing question or are wondering about beginning a new partnership with us, get in touch, and we’ll be delighted to help. We’re prepared for the future and eager to help you confidently deliver your next clinical trial.
2020 kdm communications limited
All FDA-approved biological and biosimilar products have to undergo thorough testing and cli...
The growth in the biosimilar market since 2006 has been significant. Biosimilars have no mea...